Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Genome-editing technologies have enabled the clinical development of allogeneic cellular therapies, yet the optimal gene-editing modality for multiplex editing of therapeutic T cell product manufacturing remains elusive. In this study, we conducted a comprehensive comparison of CRISPR/Cas9 nuclease and adenine base editor (ABE) technologies in generating allogeneic chimeric antigen receptor (CAR) T cells, utilizing extensive in vitro and in vivo analyses. Both methods achieved high editing efficiencies across four target genes, critical for mitigating graft-versus-host disease and allograft rejection: TRAC or CD3E , B2M , CIITA , and PVR . Notably, ABE demonstrated higher manufacturing yields and distinct off-target profiles compared to Cas9, with translocations observed exclusively in Cas9-edited products. Functionally, ABE-edited CAR T cells exhibited superior in vitro effector functions under continuous antigen stimulation, including enhanced proliferative capacity and increased surface CAR expression. Transcriptomic analysis revealed that ABE editing resulted in reduced activation of p53 and DNA damage response pathways at baseline, along with sustained activation of metabolic pathways during antigen stress. Consistently, Assay for Transposase-Accessible Chromatin using sequencing data indicated that Cas9-edited, but not ABE-edited, CAR T cells showed enrichment of chromatin accessibility peaks associated with double-strand break repair and DNA damage response pathways. In a preclinical leukemia model, ABE-edited CAR T cells demonstrated improved tumor control and extended overall survival compared to their Cas9-edited counterparts. Collectively, these findings position ABE as superior to Cas9 nucleases for multiplex gene editing of therapeutic T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This strategy reduces handling steps but does not eliminate the underlying trade-off between delivery efficiency and cellular toxicity, reinforcing the need for alternative strategies that can sustain genomic integrity and viable cell numbers across multi-step workflows.79”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [79]
In the citing paper
“Even optimized approaches consolidate multiple editing components into a single electroporation round to minimize genotoxicity and preserve cell yield.”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · cited 1×
“To account for potential differences in toxicity, immunogenicity ( 36 , 37 ), and on - and off - target editing efficiency ( 38 , 39 ) between protein and mRNA delivery, we included a group utilizing Cas9 SpyFi mRNA.”
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 1×
“To account for potential differences in toxicity, immunogenicity ( 36 , 37 ), and on - and off - target editing efficiency ( 38 , 39 ) between protein and mRNA delivery, we included a group utilizing Cas9 SpyFi mRNA.”
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Self-citationBlank, C. U., Haining, W. N., Held, W., Hogan, P. G., Kallies, A., Lugli, E., Lynn, R. C., Philip, M., Rao, A., Restifo, N. P., et al. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0221-9 · Cited by 1,603 · cited 2×
“NALM6 and HEK293T cell lines were sourced from the American Type Culture Collection (ATCC) and maintained in standard R10 culture media (RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin [50 IU/mL], 1% HEPES, and 1% Glutamax; Gibco, Life Technologies) at 37 °C in a 5% CO2 environment.”
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“These cells were then transduced with a CD19 CAR construct ( 43 , 44 ) via lentiviral vectors.”
Self-citationThe promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Richter, M. F., Zhao, K. T., Eton, E., Lapinaite, A., Newby, G. A., Thuronyi, B. W., Wilson, C., Koblan, L. W., Zeng, J., Bauer, D. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0453-z · Cited by 1,020 · cited 3×
“For subsequent experiments, 10 μ g of mRNA encoding ABE8e [TrilLink, N1 - Methylpseudouridine - Substitution, CleanCap (35)], 1.875 μ g of each sgRNA (IDT), and 100 μ L of resuspended cells were combined prior to EP.”
Influential
Research works printed but not linked: 55
- 10.1056/NEJMra1706169 · DOI · Paper page
- 10.1038/s41571-023-00754-1 · DOI · Paper page
- 10.1200/JCO.2024.42.16_suppl.6504 · doi:10.1200/jco.2024.42.16_suppl.6504
- U. Uslu, C. H. June, Beyond the blood: Expanding CAR T cell therapy to solid tumors. Nat. Biotechnol., 10.1038/s41587-024-02446-2 (2024). · DOI · Paper page
- 10.1038/s41586-023-06243-w · DOI · Paper page
- 10.1016/j.cell.2024.07.056 · DOI
- 10.1182/blood.2022016204 · DOI
- 10.1038/s41573-019-0051-2 · DOI · Paper page
- 10.1016/j.cell.2024.01.035 · DOI
- 10.1038/s41579-022-00739-4 · DOI · Paper page
- 10.1016/j.omtm.2021.10.008 · DOI
- 10.1182/blood.2022015825 · DOI
- 10.1016/j.cell.2023.08.041 · DOI · Paper page
- 10.1038/nature17946 · DOI · Paper page
- 10.1016/S1074-7613(00)80681-0 · DOI · Paper page
- 10.1158/2326-6066.CIR-18-0508 · DOI · Paper page
- 10.1093/intimm/3.4.359 · DOI
- S. Agarwal, N. Wellhausen, B. L. Levine, C. H. June, Production of human CRISPR-engineered CAR-T cells. J. Vis. Exp. 169, (2021), 10.3791/62299. · DOI
- 10.1038/s41586-021-03609-w · DOI · Paper page
- 10.1126/science.1225829 · DOI · Paper page
- 10.1126/scitranslmed.adi1145 · DOI
- 10.1158/2326-6066.CIR-24-0251 · DOI
- 10.1056/NEJMoa1215134 · DOI · Paper page
- 10.1016/j.jsbmb.2009.02.008 · DOI
- 10.1016/j.stem.2024.06.011 · DOI
- 10.1016/j.ymthe.2019.01.014 · DOI · Paper page
- 10.1186/s13059-024-03434-0 · DOI
- 10.1038/s41551-024-01277-5 · DOI
- 10.1016/j.immuni.2023.09.001 · DOI · Paper page
- 10.1182/blood.2020005185 · DOI · Paper page
- 10.1016/S1074-7613(00)00066-2 · DOI · Paper page
- 10.1016/0008-8749(88)90073-1 · doi:10.1016/0008-8749(88)90073-1
- 10.1182/blood-2010-08-300954 · DOI
- 10.1186/s13059-015-0784-0 · DOI · Paper page
- 10.4049/jimmunol.1602086 · DOI · Paper page
- 10.1016/j.cell.2021.11.016 · DOI · Paper page
- 10.1002/advs.202309004 · DOI
- 10.3389/fimmu.2017.01956 · DOI
- 10.1158/2767-9764.CRC-21-0157 · DOI
- M.-Y. Lin, H. Yoon, A. Nguyen, B. Sasu, T. Pertel, Allogeneic CAR T cells derived from younger donor T cells have more desirable T cell phenotype and better in vitro functionality (abstract #1252 in 2022 ASGCT Annual Meeting Abstracts). Mol. Ther. 30, S586 (2022).
- A. Prodeus , P205 lipid nanoparticles (LNPs) as a superior CRISPR/Cas9 delivery modality for highly efficient multiplex gene editing of T cells for adoptive cell therapy. Hum. Gene Ther. 32, 19–20 (2021).
- 10.1182/blood.2022019333 · DOI · Paper page
- S. Umetani , 327 Evaluation of ex vivo gene editing efficiency in human primary T cells by mRNA-LNP. J. ImmunoTher. Cancer 12, A380 (2024).
- 10.1038/s41551-023-01032-2 · DOI
- 10.1038/s41587-023-01756-1 · DOI
- 10.3389/fimmu.2022.1007579 · DOI · Paper page
- 10.1038/nprot.2009.22 · DOI · Paper page
- 10.1126/sciadv.ade2526 · DOI
- 10.1089/crispr.2019.0074 · DOI · Paper page
- 10.1038/s41587-020-0439-x · DOI · Paper page
- 10.1093/bioinformatics/btp616 · DOI · Paper page
- 10.1038/nbt.1630 · DOI · Paper page
- N.W. Engel Quadruple adenine base edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease engineered T cells [ATAC-seq]. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290620. Deposited 28 February 2025.
- N. W. Engel Quadruple adenine base edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease engineered T cells [RNA-seq]. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290621. Deposited 28 February 2025.
- N. W. Engel Quadruple adenine base edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease engineered T cells. BioProject NCBI. https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA1235253. Deposited 14 March 2025.
Cited by
Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.103081
Metadata
- Authors
- Engel, N. W., Steinfeld, I., Ryan, D., Anupindi, K., Kim, S., Wellhausen, N., Chen, L., Wilkins, K., Baker, D. J., Rommel, P. C., Jarocha, D., Gohil, M., Zhang, Q., Milone, M. C., Fraietta, J. A., Davis, M., Young, R. M., & June, C. H.
- Affiliations
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania
- Agilent Research Laboratories
- Institute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2025-05-05
- Volume
- 122
- Issue
- 20
- ISSN
- 0027-8424
- 1091-6490
- Cited by
- 39
- References
- 30
- Language
- en
- Funders
- US NIH, National Cancer Institute (1-U54 CA244711)
- Agilent Foundation (Thought Leader Award 2020)
- Gilead | Kite Pharma (Sponsored Research)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells. https://app.cochat.ai/papers/10.1073/pnas.2427216122
- The paper
- Engel, N. W., Steinfeld, I., Ryan, D., Anupindi, K., Kim, S., Wellhausen, N., Chen, L., Wilkins, K., Baker, D. J., Rommel, P. C., Jarocha, D., Gohil, M., Zhang, Q., Milone, M. C., Fraietta, J. A., Davis, M., Young, R. M., & June, C. H. (2025). Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2427216122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.